Production Linked Incentive Schemes have Strengthened India’s Pharmaceutical, Bulk Drugs and Medical Devices Manufacturing Ecosystem

1. At a Glance

• Three PLI schemes run by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers support Bulk Drugs (KSMs/DIs/APIs), Pharmaceuticals and Medical Devices manufacturing. [1]
• Their stated aims are to raise investment, prevent supply disruption of critical APIs, cut import dependence and encourage technology adoption, under Make in India and Atmanirbhar Bharat. [1]
• Combined outlay is ₹6,940 cr + ₹15,000 cr + ₹3,420 cr = ₹25,360 cr (arithmetic from the figures in [1]). Investment under the Pharmaceuticals scheme is far above target. [1]
• For UPSC this is a standard example for industrial policy, import substitution, supply-chain resilience and healthcare self-reliance.

2. Why in the News

• PIB release of 25 Sep 2026 reports scheme progress as of June 2026 and says the PLI schemes have strengthened domestic pharma and MedTech manufacturing. [1]
• Reported outcomes:
• Pharmaceuticals scheme: ₹46,744 cr actual investment. [1]
• Bulk Drugs scheme: ₹5,210.74 cr invested. [1]
• Medical Devices scheme: production of 57 unique devices has commenced. [1]

3. Background & Evolution

• Rationale: reduce import dependence, particularly for APIs and other essential pharmaceutical building blocks, and build supply-chain resilience. [1]
• Milestones:
• 2020: PLI Scheme for Bulk Drugs approved, outlay ₹6,940 cr. [1]
• 2020: PLI Scheme for Medical Devices approved, outlay ₹3,420 cr. [1]
• 2021: PLI Scheme for Pharmaceuticals approved, outlay ₹15,000 cr. [1]
• FY 2022-23: performance period began under the Pharmaceuticals scheme. [1]

• June 2026: cut-off date for the progress data in the release. [1]

• Predecessor schemes are not covered in the source, so they are omitted here.

4. Core Static Facts

• Bulk Drugs: 39 projects for 28 APIs/KSMs have been commissioned. [1]
• Fermentation-based products now made domestically: Penicillin-G, Clavulanic Acid, Rifampicin. [1]
• Medical Devices incentive: 5% on incremental sales of eligible devices made in India, for five years. [1]
• Medical Devices segments:
• Cancer care/radiotherapy devices.
• Radiology and imaging devices.
• Anaesthesia, cardio-respiratory and renal care devices.

• Implants, including implantable electronic devices. [1]

• Implementing body: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. [1]

5. Multi-Dimensional Analysis

Economic

• Pharmaceuticals PLI investment is about 2.7 times the target (₹46,744 cr against ₹17,275 cr). [1]
• Export share of sales:
• Pharmaceuticals: about 64% (₹2,57,370 cr of ₹4,02,869 cr), which shows an export orientation.
• Bulk Drugs: about 15% (₹560.16 cr of ₹3,792.49 cr), which shows the scheme is still mainly import-substituting.

• Both percentages are derived from [1].

• Employment: 1,21,294 jobs under the Pharmaceuticals scheme and about 5,127 under Bulk Drugs. [1]

Strategic / Supply-chain

• The Bulk Drugs scheme targets critical APIs to prevent supply disruption. [1]
• Domestic fermentation capacity for Penicillin-G, Clavulanic Acid and Rifampicin, earlier largely import-dependent, reduces exposure to concentrated import sources. [1]

Scientific / Technological

• The Pharmaceuticals scheme steers the industry towards biopharmaceuticals, complex generics and orphan drugs, that is, higher value-addition. [1]
• Medical devices now made in India include MRI, CT, Cath Labs, Linear Accelerators, C-Arms, mammography, ultrasound, anaesthesia machines and heart valves. [1]
• Global firms (GE Healthcare, Siemens, Philips, Varex, Nipro, Omron) set up or expanded operations, and the release refers to technology transfer. [1]

Administrative / Regional

• Commissioned projects are cited in Visakhapatnam, Andhra Pradesh. [1]
• The scheme is centrally run through the Department of Pharmaceuticals. [1]
• Caveats:
• The release reports investment, sales and jobs but no cost per job or incentive disbursed, so incentive cost-effectiveness cannot be judged from it.
• The excerpt does not give the status of the Medical Devices scheme's investment or sales.

Inclusion (MSMEs)

• 20 of 55 selected applicants under the Pharmaceuticals scheme are MSMEs. [1]

6. Recent Developments (last 12-18 months)

• 25 Sep 2026: PIB release consolidating progress of all three schemes. [1]
• June 2026: data cut-off, with ₹46,744 cr invested under the Pharmaceuticals scheme and 39 Bulk Drugs projects commissioned. [1]
• Named beneficiaries with expanded capacity:
• Sun Pharma, Aurobindo, Dr. Reddy's, Lupin, Cipla, Intas and Torrent (complex generics, biosimilars, auto-immune medicines). [1]

• Lyfius Pharma, Kinvan, Andhra Organics, Meghmani LLP and Centrient (Penicillin G, Clavulanic Acid, Sulfadiazine, Atorvastatin, PAP). [1]

• The excerpt was truncated and I did not run searches, so other 2025-26 events are not covered.

7. Prelims Hooks

• PLI Scheme for Bulk Drugs was approved in 2020 with an outlay of ₹6,940 crore. [1]
• The Bulk Drugs scheme covers 41 identified critical products. [1]
• 48 projects are approved under the Bulk Drugs scheme, and 39 projects for 28 APIs/KSMs have been commissioned. [1]
• Penicillin-G, Clavulanic Acid and Rifampicin are fermentation-based products now produced domestically under the Bulk Drugs scheme. [1]
• PLI Scheme for Pharmaceuticals was approved in 2021 with an outlay of ₹15,000 crore. [1]
• 55 applicants, including 20 MSMEs, were selected under the Pharmaceuticals scheme. [1]
• The Pharmaceuticals scheme's performance period began in FY 2022-23. [1]
• The Pharmaceuticals scheme attracted ₹46,744 cr investment against a target of ₹17,275 cr, and created 1,21,294 jobs (June 2026). [1]
• PLI Scheme for Medical Devices was approved in 2020 with an outlay of ₹3,420 crore. [1]
• Medical Devices PLI gives a 5% incentive on incremental sales for five years. [1]
• Medical Devices PLI covers four segments: cancer care/radiotherapy; radiology and imaging; anaesthesia, cardio-respiratory and renal care; implants including implantable electronic devices. [1]
• 57 unique medical devices have commenced production under the Medical Devices scheme. [1]
• All three schemes are implemented by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. [1]

8. Made in India, Still Made From Chinese Inputs

• Making the medicine here is not the same as making the raw material here
• About two-thirds of India's imports of bulk drugs and drug intermediates still come from China [2].
• A company can win a Pharmaceuticals PLI incentive for selling a finished complex generic, while the KSM (key starting material — the first chemical the whole drug is built from) inside it is bought from China.

• So the big ₹4,02,869 cr sales number under the Pharmaceuticals scheme does not by itself prove the supply chain is safe [1].

• Only part of the critical list is actually covered so far

• The Bulk Drugs scheme identified 41 critical products [1].
• Domestic capacity has been built for 28 of those 41 [3].

• The other 13 are still open. For those, a supply cut abroad hits India the same way it did in 2020.

• The reason for buying from China is price, not habit

• The government's own answer says the imports are "mainly due to economic considerations" [2].
• That means an Indian plant must beat a Chinese price, not just exist. A plant that only survives on the incentive has not solved the problem.

9. The Money Question the Release Leaves Out

• We are told what came in, not what was paid out
• Public money committed across the three schemes is ₹25,360 cr [1].
• The release reports investment, sales and jobs, but not one rupee of incentive actually disbursed [1].

• Without the disbursed figure you cannot work out cost per job or cost per rupee of extra output. So "the scheme worked" cannot be tested, only believed.

• Beating the target by 2.7 times cuts both ways

• Pharmaceuticals PLI drew ₹46,744 cr against a ₹17,275 cr target [1].
• One reading: the incentive pulled in huge money.

• The other reading: if firms invested nearly three times what the scheme asked for, some of that investment was coming anyway, and the subsidy paid for it a second time. The release gives no data to settle this.

• Incremental sales is an easy base to beat

• Medical Devices PLI pays 5% on incremental sales — sales above a base year — for five years [1].
• In a sector growing on its own, sales rise above the base without any new factory. The incentive can reward ordinary growth.

10. Medical Devices Is the Weakest of the Three Schemes

• The biggest import problem got the smallest purse
• India imports about 86% of its medical device requirement [3].
• Yet Medical Devices PLI has the smallest outlay of the three: ₹3,420 cr, against ₹15,000 cr for Pharmaceuticals [1].

• A 5% sales incentive is thin support for products like MRI and Linear Accelerators, which need heavy machines, precision parts and years before the first sale.

• The release itself is silent on the numbers that matter

• For this scheme it reports only that 57 unique devices have started production [1].
• It gives no investment figure, no sales figure and no jobs figure — the three things it does report for the other two schemes [1].

• "Production has commenced" tells you a line was switched on. It does not tell you whether India now makes these devices at a scale that replaces imports.

• Assembly is not manufacture

• GE Healthcare, Siemens, Philips and others set up or expanded here [1].
• If the high-value part — the detector, the magnet, the chip — is still imported and only fitted together in India, import dependence moves down the chain instead of ending.

11. What Happens After the Five Years of Incentive End

• The support has a fixed end date
• The Medical Devices incentive runs for five years [1]; the Pharmaceuticals performance period began in FY 2022-23 [1].

• After that the Indian plant must stand on its own cost, against a Chinese supplier who is cheaper for plain economic reasons [2].

• Fermentation is where this bites hardest

• Penicillin-G, Clavulanic Acid and Rifampicin are fermentation-based and are now made in India again [1].
• Fermentation needs huge tanks, lots of power and constant running to be cheap. Small volumes cost more per kilo.

• So the real test is not whether these plants opened. It is whether they are still running in year six without a subsidy.

• What would show the scheme truly worked

• Bulk Drugs exports are only about 15% of its sales (₹560.16 cr of ₹3,792.49 cr) [1].
• If an Indian API is good enough to sell abroad against world prices, it can survive without support at home. Rising export share is the honest signal to watch.

12. The Case That the Schemes Deserve More Credit

• The strongest objection first: critics say PLI is just a subsidy that pays firms for what the market was doing anyway, and leaves India still buying Chinese inputs [2].
• But some things would not have happened on their own
• Penicillin-G is the base of a very large share of common antibiotics. India had stopped making it and now makes it again [1]. No private firm restarts a loss-making fermentation plant without support.

• 39 projects covering 28 APIs/KSMs have been commissioned — physical plants, not announcements [1].

• The export number answers part of the criticism

• Under the Pharmaceuticals scheme, about 64% of sales are exports (₹2,57,370 cr of ₹4,02,869 cr) [1].

• Exports are sold at world prices against world rivals. That is harder to fake than domestic sales behind a tariff wall.

• What the critics are right about: the scheme has fixed the finished-drug end far better than the raw-material end, and it has done least where import dependence is worst — medical devices, at 86% [3].

13. What the Department of Pharmaceuticals Should Fix Next

• Publish the incentive actually disbursed, scheme by scheme
• Right now only investment, sales and jobs are released [1].

• Add disbursement, and anyone can compute cost per job and cost per rupee of output. Parliament and CAG can then judge value for money instead of taking the claim on trust.

• Finish the Bulk Drug Parks before the PLI plants lose their incentive

• The Scheme for Promotion of Bulk Drug Parks has a ₹3,000 cr outlay and covers three parks — Himachal Pradesh, Gujarat and Andhra Pradesh — with up to ₹1,000 cr assistance per park [4].
• The parks give shared steam, power and effluent treatment, which is exactly what cuts the running cost of a fermentation plant.

• PLI pays per unit sold for a few years; the park lowers cost permanently. The subsidy ends in five years, so the parks must be working before then.

• Cover the remaining 13 of the 41 critical products

• Capacity exists for 28 [3]. The Department should say publicly which 13 have no bidder and why, and redesign the incentive for those, since a critical product with no maker is the exact gap the scheme was created to close.

• Move the Medical Devices incentive deeper into the product

• Today the 5% is paid on sales of the finished device [1].
• Tying part of it to India-made high-value components would push firms past assembly, in a sector where 86% is still imported [3].

14. Anchors for Answers

• Data: About two-thirds of India's bulk drug and drug intermediate imports come from China, mainly for cost reasons [2]
• Data: India imports roughly 86% of its medical device requirement [3]
• Data: Domestic capacity built for 28 of the 41 identified critical bulk drugs [3]
• Data: Pharmaceuticals PLI — ₹46,744 cr invested against a ₹17,275 cr target; 64% of its ₹4,02,869 cr sales are exports (June 2026) [1]
• Scheme: Scheme for Promotion of Bulk Drug Parks — ₹3,000 cr outlay, three parks (Himachal Pradesh, Gujarat, Andhra Pradesh), up to ₹1,000 cr each, for shared infrastructure that cuts running cost after PLI ends [4]
• Comparison: Medical Devices PLI gets the smallest outlay (₹3,420 cr) of the three schemes [1] even though import dependence is highest there at 86% [3]

15. Mains Relevance

• GS-III: Indian Economy, covering industrial policy, manufacturing, investment models, and infrastructure and supply chains. Science & Technology applications also apply.
• GS-II: Health, and Government policies and interventions.
• Question stems:
• Production Linked Incentive schemes in pharmaceuticals and medical devices have reduced import dependence but raise questions of fiscal cost and sustainability. Discuss.
• Critically examine how the PLI Scheme for Bulk Drugs contributes to supply-chain resilience in critical APIs.
• How far can PLI schemes deliver Atmanirbhar Bharat in healthcare manufacturing? Evaluate with reference to medical devices.

16. Related Topics to Study Next

• PLI schemes in other sectors: compare design (incremental sales, performance periods) across sectors.
• Bulk Drug Parks scheme: complements API PLI through shared infrastructure.
• Atmanirbhar Bharat / Make in India: the policy framework named in the release. [1]
• Medical Devices Rules and regulation: the regulatory side of domestic device manufacturing.
• Supply-chain resilience and import dependence: the strategic rationale. [1]
• MSME support: 20 MSMEs were selected under the Pharmaceuticals scheme. [1]
• WTO rules on subsidies: relevant to export-linked incentives and the export share of sales.
• Intellectual property and biosimilars: links to the high-value segments the Pharmaceuticals scheme targets. [1]

17. Common Errors / Trap Areas

• Ministry: it is the Department of Pharmaceuticals under Chemicals & Fertilizers, not the Health Ministry. [1]
• Years: Bulk Drugs and Medical Devices were approved in 2020, while Pharmaceuticals was approved in 2021. [1]
• Outlays: ₹6,940 cr (Bulk Drugs), ₹15,000 cr (Pharmaceuticals) and ₹3,420 cr (Medical Devices) are easily swapped. [1]
• Incentive basis: the Medical Devices incentive is 5% on incremental sales for five years, not on capital expenditure. [1]
• Committed versus actual investment: the Bulk Drugs figures are ₹5,210.74 cr against ₹4,330 cr committed, and the Pharmaceuticals figures are ₹46,744 cr against ₹17,275 cr targeted. [1]